The European Commission's appeal against court-ordered disclosures of its COVID-19 vaccine contracts should be dismissed, a senior legal adviser to the EU's highest court has said, according to a Reuters report on the opinion.

The recommendation comes from an advocate general at the Court of Justice of the European Union, the Luxembourg-based institution that serves as the final arbiter on EU law. Advocate generals issue non-binding opinions on pending cases; the Court's judges deliberate independently and deliver the binding judgment at a later date.

What is the case about?

The dispute centers on the Commission's refusal to release details of the purchase contracts it concluded with pharmaceutical companies for COVID-19 vaccines during the pandemic. The contracts, negotiated on behalf of EU member states, involved billions of euros in public money and shaped the bloc's vaccination campaign.

Transparency advocates and lawmakers pressed for the contracts to be published, arguing that the public interest in scrutiny of such large public expenditures outweighed commercial confidentiality concerns raised by the manufacturers and the Commission.

The Commission resisted full disclosure and, after losing before a lower EU court, took the matter to the Court of Justice on appeal. The advocate general's opinion now recommends that the appeal be dismissed.

What does the opinion change?

By itself, an advocate general's opinion changes nothing formally. The Court of Justice follows the adviser's recommendation in the majority of cases, but it is not bound to do so. If the judges agree and dismiss the appeal, the earlier ruling requiring greater disclosure of the vaccine contracts would stand, and the Commission would have exhausted its avenue of appeal.

The opinion signals that the Court may be prepared to affirm a demanding standard of transparency for public procurement conducted in emergency conditions — even where powerful commercial interests argue that confidentiality clauses should prevail.

Why does it matter for practitioners?

For EU public law practitioners, the case sits at the intersection of two established principles: the public's right of access to documents held by EU institutions, and the protection of commercial interests under the EU's transparency rules. The advocate general's recommendation suggests the balance tips toward disclosure when contracts involve substantial public funds and matters of overriding public concern, such as a pandemic response.

Lawyers advising pharmaceutical companies and other contractors dealing with EU institutions will watch the final judgment closely. If the Court confirms the dismissal, contractual confidentiality undertakings given to the Commission may offer weaker protection against later disclosure requests than clients have assumed. Counsel negotiating future agreements with EU bodies may need to price that disclosure risk into terms and dispute confidentiality carve-outs at the drafting stage.

For the Commission, an adverse final ruling would close a chapter of litigation that has drawn political scrutiny of its handling of vaccine procurement records. The institution has defended its approach on the grounds that it released substantial portions of the contracts while withholding commercially sensitive passages.

What happens next?

The Court of Justice will deliver its judgment in due course. No date for the ruling was indicated in the report. Until then, the opinion stands as guidance only — but it marks the clearest signal yet from the EU's judicial apparatus that the era of pandemic-era secrecy around vaccine contracts may be drawing to a close.